Antibodies as key mediators of protection against

Humans Mycobacterium tuberculosis / immunology Antibodies, Bacterial / immunology Tuberculosis / immunology BCG Vaccine / immunology Animals Immunity, Innate Vaccination Biomarkers
LTBI (latent TB infection) active tuberculosis (ATB) antibody biomarkers serology systems immunology tuberculosis

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2024
Historique:
received: 10 05 2024
accepted: 13 08 2024
medline: 17 9 2024
pubmed: 17 9 2024
entrez: 17 9 2024
Statut: epublish

Résumé

Tuberculosis (TB) is caused by infection with the bacterial pathogen

Identifiants

DOI: 10.3389/fimmu.2024.1430955 PMID: 39286260 PMC: PMC11402706
pubmed: 39286260
doi: 10.3389/fimmu.2024.1430955
pmc: PMC11402706
doi:

Substances chimiques

Antibodies, Bacterial 0
BCG Vaccine 0
Biomarkers 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1430955

Informations de copyright

Copyright © 2024 Wang, Nag, Baldwin, Coler and McNamara.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Auteurs

Qixin Wang (Q)

Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, United States.

Deepika Nag (D)

Seattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle, WA, United States.

Susan L Baldwin (SL)

Seattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle, WA, United States.

Rhea N Coler (RN)

Seattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle, WA, United States.
Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, United States.
Department of Global Health, University of Washington, Seattle, WA, United States.

Ryan P McNamara (RP)

Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Antibodies as key mediators of protection against
questionsmedicales.fr › Bactéries › Bactéries à Gram positif › Bâtonnets à Gram positif › Bâtonnets asporogènes à Gram positif › Bâtonnets asporogènes réguliers à Gram positif › Mycobacteriaceae › Mycobacterium › Mycobacterium tuberculosis › Antibodies as key mediators of protection against
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps antibactériens › Antibodies as key mediators of protection against
questionsmedicales.fr › Infection › Infections bactériennes et mycoses › Infections bactériennes › Infections bactériennes à Gram positif › Infections à Actinomycetales › Infections à Mycobacterium › Tuberculose › Antibodies as key mediators of protection against
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antibactériens › Vaccins antituberculeux › Vaccin BCG › Antibodies as key mediators of protection against
questionsmedicales.fr › Eucaryotes › Animaux › Antibodies as key mediators of protection against
questionsmedicales.fr › Phénomènes du système immunitaire › Immunité › Immunité innée › Antibodies as key mediators of protection against
questionsmedicales.fr › Environnement et santé publique › Santé publique › Pratiques en santé publique › Prévention primaire › Immunisation › Vaccination › Antibodies as key mediators of protection against
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Antibodies as key mediators of protection against